7 March 2025
Key Implications of the First Omnibus Package on the Corporate Sustainability Due Diligence Directive
1 min read
Last week saw the publication of the European Commission’s much-anticipated “Omnibus” package.
Last week saw the publication of the European Commission’s much-anticipated “Omnibus” package which aims to simplify EU sustainability reporting regulations. We’ve had a detailed look at the proposals in this package to see what exactly the European Commission wants to change in the Corporate Sustainability Due Diligence Directive (“CSDDD”). After setting out the main aspects of the CSDDD, as it currently stands, as well as the key changes proposed by the European Commission, we give our thoughts on the broader implications of these changes for businesses.
Attachments:
->
News & insights
1 min
read
read
Briefings
VBB secures lowest anti-dumping duty for Hankook in EU passenger car tyre investigation
7 July 2026
2 min
read
read
Briefings
Lithuanian Competition Authority Fines Pharmacy Association and Individual Firms for Collusion while Participating in Margin-setting Procedure
14 December 2022
2 min
read
read
Briefings
France - Supreme Court Allows Follow-on Damages Action by Health Insurer in Wake of Sanofi’s Denigration Strategy against Generic Rivals
13 October 2023
2 min
read
read
Briefings
European Commission Sends Statement of Objections to Teva over Abusive Patent Filings and Disparagement of Generic Competitors
11 October 2022
1 min
read
read
Briefings
F. Hoffmann-La Roche and Novartis (Avastin - Lucentis) – ECJ Finds Concerted Efforts to Restrict Off-label Use of Medicinal Products Likely to Breach Competition Rules
24 January 2018
3 min
read
read
Briefings
Advocate General Recommends to Court of Justice of European Union to Allow Reimbursement of Off Label Use of Medicine for Purely Budgetary Reasons
30 August 2018
3 min
read
read
Briefings
“National Healthcare Insurance Systems Are Allowed To Reimburse Off-Label Use of Medicine” Says ECJ
21 November 2018
3 min
read
read
Briefings
French Competition Authority - Genentech, Novartis and Roche Fined EUR 444 million in Saga Involving Wet Age-Related Macular Degeneration
9 September 2020
